Low-dose pancreatic polypeptide inhibits food intake in man

David R. Jesudason, Mariana P. Monteiro, Barbara M C McGowan, Nicola M. Neary, Adrian J. Park, Elena Philippou, Caroline J. Small, Gary S. Frost, Mohammad A. Ghatei, Stephen R. Bloom

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)


Pancreatic polypeptide (PP) is a gut hormone released from the pancreas in response to food ingestion and remains elevated for up to 6 h postprandially. Plasma levels are elevated in patients with pancreatic tumours. An intravenous infusion of PP has been reported to reduce food intake in man, suggesting that PP is a satiety hormone. We investigated whether a lower infusion rate of PP would induce significant alterations in energy intake. The study was randomised and double-blinded. Fourteen lean fasted volunteers (five men and nine women) received 90 min infusions of PP (5 pmol/kg per min) and saline on two separate days. The dose chosen was half that used in a previous human study which reported a decrease in appetite but at supra-physiological levels of PP. One hour after the end of the infusion, a buffet lunch was served and energy intake measured. PP infusion was associated with a significant 11% reduction in energy intake compared with saline (2440 (SE 200) v. 2730 (SE 180) kJ; P<0.05). Preprandial hunger as assessed by a visual analogue score was decreased in the PP-treated group compared to saline. These effects were achieved with plasma levels of PP within the pathophysiological range of pancreatic tumours.

Original languageEnglish
Pages (from-to)426-429
Number of pages4
JournalBritish Journal of Nutrition
Issue number3
Publication statusPublished - Mar 2007


  • Energy intake
  • Pancreatic polypeptide
  • Satiety


Dive into the research topics of 'Low-dose pancreatic polypeptide inhibits food intake in man'. Together they form a unique fingerprint.

Cite this